All participants were believed — consistent with evidence-based guidelines — to require antibiotic treatment. When PCT-arm patients had PCT levels >0.25 µg/L, a bacterial infection was ...

PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announced the clinical results ...

In some cases, Phogat says, vaccines might be only one arm of an approach to patient ... “Bacteria continue to develop resistance to antibiotics, whereas the role of vaccines as a tool to ...

Meanwhile, in another analysis of the three-arm trial, the use of C-reactive protein (CRP) monitoring atop standard care made no difference in the duration of antibiotic therapy (10.6 days vs 10.7 ...